Orszulak Luiza, Włodarczyk Patryk, Hachuła Barbara, Lamrani Taoufik, Jurkiewicz Karolina, Tarnacka Magdalena, Hreczka Marek, Kamiński Kamil, Kamińska Ewa
Institute of Chemistry, Faculty of Science and Technology, University of Silesia in Katowice, Szkolna 9 40-007, Katowice, Poland.
Institute of Non Ferrous Metals, Sowinskiego 5 44-100, Gliwice, Poland.
Eur J Pharm Biopharm. 2025 Feb;207:114581. doi: 10.1016/j.ejpb.2024.114581. Epub 2024 Nov 27.
This paper presents an innovative approach that utilizes self-synthesized homopolymers of polyvinylpyrrolidone (PVP) with different architectures as effective matrices for inhibiting the crystallization of naproxen (NAP). We have thoroughly investigated amorphous solid dispersions containing NAP and (i) self-synthesized linear PVP, (ii) self-synthesized three-armed star-shaped PVP, and (iii) self-synthesized linear PVP with a mass (M) corresponding to the length of one arm of the star polymer, as well as (iv) commercial linear PVP K30 as a reference. Differential scanning calorimetry, X-ray diffraction, and infrared spectroscopy studies, as well as molecular dynamics simulations were conducted to gain comprehensive insights into the thermal and structural properties, as well as intermolecular interactions in the NAP-PVP systems. The main purpose of all experiments was to assess the impact of macromolecule structure (topology, molecular weight) on the kinetics of the crystallization of NAP - a drug that is very difficult to vitrify. Our studies clearly showed that the most effective matrix in inhibiting the NAP crystallization is linear, self-synthesized PVP with higher molecular weight (M) similar to that of the commercial PVP K30, but lower, strictly controlled dispersity. We also found that crystallization of API proceeds at a similar pace for the binary mixture composed of a star-shaped PVP and linear polymer with M corresponding to M of one arm of the star-shaped macromolecule in the vicinity of the T. The obtained data highlight the key role of polymer structure in designing new pharmaceutical formulations.
本文提出了一种创新方法,该方法利用具有不同结构的聚乙烯吡咯烷酮(PVP)自合成均聚物作为抑制萘普生(NAP)结晶的有效基质。我们深入研究了含有NAP和(i)自合成线性PVP、(ii)自合成三臂星形PVP、(iii)质量(M)与星形聚合物一条臂长度相当的自合成线性PVP以及(iv)市售线性PVP K30作为对照的无定形固体分散体。进行了差示扫描量热法、X射线衍射和红外光谱研究以及分子动力学模拟,以全面了解NAP - PVP体系的热性能、结构性能以及分子间相互作用。所有实验的主要目的是评估大分子结构(拓扑结构、分子量)对NAP结晶动力学的影响,NAP是一种极难玻璃化的药物。我们的研究清楚地表明,抑制NAP结晶最有效的基质是自合成的线性PVP,其分子量(M)与市售PVP K30相似,但分散度更低且严格可控。我们还发现,对于由星形PVP和线性聚合物组成的二元混合物,在T附近,当线性聚合物的M与星形大分子一条臂的M相对应时,活性药物成分(API)的结晶速度相似。所得数据突出了聚合物结构在设计新型药物制剂中的关键作用。